NZ617581B2 - Radiolabelled glutaminyl cyclase inhibitors - Google Patents
Radiolabelled glutaminyl cyclase inhibitors Download PDFInfo
- Publication number
- NZ617581B2 NZ617581B2 NZ617581A NZ61758112A NZ617581B2 NZ 617581 B2 NZ617581 B2 NZ 617581B2 NZ 617581 A NZ617581 A NZ 617581A NZ 61758112 A NZ61758112 A NZ 61758112A NZ 617581 B2 NZ617581 B2 NZ 617581B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- imaging
- detection
- formula
- glutaminyl cyclase
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 40
- 102000003642 EC 2.3.2.5 Human genes 0.000 title claims abstract description 26
- 108010081484 EC 2.3.2.5 Proteins 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 123
- 238000001514 detection method Methods 0.000 claims abstract description 42
- 238000003384 imaging method Methods 0.000 claims abstract description 23
- 208000009025 Nervous System Disease Diseases 0.000 claims abstract description 19
- 206010029305 Neurological disorder Diseases 0.000 claims abstract description 19
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 14
- 239000012216 imaging agent Substances 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 201000010374 Down syndrome Diseases 0.000 claims abstract description 6
- 201000001971 Huntington's disease Diseases 0.000 claims abstract description 5
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims abstract description 5
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims abstract description 5
- 208000010512 familial Danish Dementia Diseases 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims description 22
- 210000001519 tissues Anatomy 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 13
- 210000004556 Brain Anatomy 0.000 claims description 11
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 11
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 claims description 9
- 102000013498 tau Proteins Human genes 0.000 claims description 6
- 108010026424 tau Proteins Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 206010057668 Cognitive disease Diseases 0.000 claims description 4
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 238000004611 spectroscopical analysis Methods 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 49
- 239000002904 solvent Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 125000004452 carbocyclyl group Chemical group 0.000 description 25
- 239000000543 intermediate Substances 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 23
- 150000002367 halogens Chemical class 0.000 description 23
- 238000002600 positron emission tomography Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- -1 75Br Chemical compound 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 125000000217 alkyl group Chemical group 0.000 description 20
- 125000001072 heteroaryl group Chemical group 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 102100006337 CASP5 Human genes 0.000 description 8
- 101700077251 CASP5 Proteins 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000001809 detectable Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 125000004043 oxo group Chemical group O=* 0.000 description 6
- 239000000700 tracer Substances 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000005133 alkynyloxy group Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000000155 isotopic Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N Trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000008079 hexane Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 101700083699 HIS6 Proteins 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 101710008935 hisHF Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 230000001817 pituitary Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- BVUGBCYESKXQKQ-UHFFFAOYSA-N propoxycyclohexatriene Chemical group CCCOC1=CC=C=C[CH]1 BVUGBCYESKXQKQ-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- YCKRFDGAMUMZLT-BJUDXGSMSA-N (18)F Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 208000003808 Amyloid Neuropathy Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 240000006432 Carica papaya Species 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental Effects 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000004977 physiological function Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- RURHILYUWQEGOS-VOTSOKGWSA-N (E)-3-(4-methylphenyl)prop-2-enoic acid Chemical group CC1=CC=C(\C=C\C(O)=O)C=C1 RURHILYUWQEGOS-VOTSOKGWSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 1
- WFRXSXUDWCVSPI-UHFFFAOYSA-N 3H-benzimidazol-5-amine Chemical compound NC1=CC=C2NC=NC2=C1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N 4-Methoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- FGXZWMCBNMMYPL-UHFFFAOYSA-N 4-propoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1 FGXZWMCBNMMYPL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000008581 Brain Disease Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 208000005145 Cerebral Amyloid Angiopathy Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N Cyclamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 206010022498 Insulinoma Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- 206010023497 Kuru Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N N-Propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 208000008864 Scrapie Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 238000011001 backwashing Methods 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000002354 carica papaya Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- OQOCQBJWOCRPQY-UHFFFAOYSA-N diethyl 2-methyl-3-oxosuccinate Chemical compound CCOC(=O)C(C)C(=O)C(=O)OCC OQOCQBJWOCRPQY-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000003557 neuropsychological Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960000854 protirelin Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SKBXVAOMEVOTGJ-UHFFFAOYSA-N ξ-Pinol Chemical compound CC1=CCC2C(C)(C)OC1C2 SKBXVAOMEVOTGJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Abstract
The disclosure relates to radiolabelled imidazole glutaminyl cyclase (QC) inhibitors for use as imaging agents. The disclosure also relates to pharmaceutical compositions comprising these compounds and the use of these compounds for imaging and detection in neurological disorders, such as Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, Down Syndrome and Huntington's disease. s disease, Familial British Dementia, Familial Danish Dementia, Down Syndrome and Huntington's disease.
Description
W0 20/2/163773
RADLOLABELLED GLUTAMLIT:, Li CYCLASE TnnLBLTORS
Field of the invention
The invention relates to the use of radiolabelled glutsminyl cyclase (QC) inhibitors as
imaging agents, in particular but not exclusively as medical imaging agents for the detection
of neurological disorders. The invention also relates to pharmaceutical compositions
comprising said radiolabelled inhibitors and to methods and kits for detecting neurological
disorders.
Background of the invention
Glutaminyl cyclase (QC, EC 23.2.5) catalyzes the intramolecular cyclization of N-terminal
glutamine residues into pyroglutamic acid (PGIu*) liberating ammonia. A QC was first isolated
by Messer from the latex of the tropical plant Carloa papaya in 1963 (Messer, M. 1963
Nature 4874, 1299). 24 years later, a corresponding enzymatic activity was discovered in
animal pituitary (Busby, W. H. J. at a1.1987 J Biol Chem 262,8532-8536; Fischer, W. H. and
Spiess, J. 1987 Proc Natl ACad Sci U S A 84,3628-3632). For the mammalian QC, the
conversion of Gin into PGIu by QC could be shown for the precursors of TRH and GnRH
(Busby, W. H. J. at a1.1987 J Biol Chem 262,8532-8536; Fischer, W. H. and Spiess, J. 1987
Proc Natl ACad Sci U S A 84,3628-3632). In addition, initial localization experiments of QC
revealed a co-localization with its putative products of catalysis in bovine pituitary, further
improving the suggested function in peptide hormone synthesis (BOGkers, T. M. at a1.1995 J
Neuroendocrin017,445-453). In contrast, the physiological function of the plant QC is less
clear. In the case of the enzyme from C. papaya, a role in the plant defense against
pathogenic microorganisms was suggested (EI Moussaoui, A. at a1.2001 Cell Mol Life Sci 58,
556-570). Putative QCs from other plants were identified by sequence comparisons recently
(Dahl, S. W. at a1.2000 Protein Expr Purif 20,27-36). The physiological function of these
enzymes, however, is still ambiguous
The QCs known from plants and animals show a strict specificity for L-Glutamine in the N-
terminal position of the substrates and their kinetic behavior was found to obey the Michaelis-
Meriten equation (Pohl, T. at a1. 1991 Proc Natl ACad Sci U S A 88,10059-, 0063; Consalvo,
A. P. at a1.1988 Anal Biochem 175,131-138; Gololobov, M. Y. at a1.1996 Biol Chem Hoppe
Seyler 377,395-398). A comparison of the primary structures of the QCs from C. papaya and
that of the highly conserved QC from mammals, however, did not reveal any sequence
hornology (Dahl, S. W. at a1.2000 Protein Expr Purif 20,27-36). Whereas the plant QCs
W0 21/12/163773 PCT/EP21112/1159649
appear to belong to a new enzyme family (Dahl, S. W. at a1.2000 Protein Expr Purif 20,27-
36), the mammalian QCs were found to have a pronounced sequence hornology to bacterial
aminopeptidases (Bateman, R. C. at a1.2001 Biochemistry 40,1,246,1250), leading to the
conclusion that the QCs from plants and animals have different evolutionary origins.
Recently, it was shown that recombinant human QC as well as QC-activity from brain
extracts catalyze both, the N-terminal glutaminyl as well as glutamate cyclization. Most
striking is the finding, that cyclase-catalyzed Glut-conversion is favored around pH 6.0 while
Gini-conversion to PGIu-derivatives occurs with a pH-optimum of around 8.0. Since the
formation of PGIu-AD-related peptides can be suppressed by inhibition of recombinant human
QC and QC-activity from pig pituitary extracts, the enzyme QC is a target in drug
development for treatment of Alzheimer's disease.
Alzheimer's disease (AD) is the most common form of dementia and is an incurable,
degenerative, and terminal disease. In 2006, there were 26.6 million sufferers worldwide.
Alzheimer's is predicted to affect I in 85 people global Iy by 2050. Alzheimer's disease is
usually diagnosed clinical Iy from the patient history, collateral history from relatives, and
clinical observations, based on the presence of characteristic neurological and
neuropsychological features and the absence of alternative conditions. Assessment of
intellectual functioning including memory testing can further characterise the state of the
disease.
More recently, imaging has become a valuable tool in the diagnosis of Alzheimer's disease.
For example, when available as a diagnostic tool, single photon emission computed
tomography (SPECT) and positron emission tomography (PET) neuroimaging may be used
to confirm a diagnosis of Alzheimer's in conjunction with evaluations involving mental status
examination. In a person already having dementia, SPECT appears to be superior in
differentiating Alzheimer's disease from other possible causes, compared with the usual
attempts employing mental testing and medical history analysis.
A new technique known as PiB PET has been developed for directly and clearly imaging ^-
amyloid deposits in vivo using a tracer that binds selectively to the A13 deposits. The PiB-PET
compound uses ''c PET scanning. Recent studies suggest that PiB-PET is 8691, accurate in
predicting which people with mild cognitive impairment will develop Alzheimer's disease
within two years, and 92% accurate in ruling out the likelihood of developing Alzheimer's.
W0 2/1/21163773
A similar PET scanning radiopharmaceutical compound called (E)(2-(6-(2-(2-(2-([ F]-
''F Av-
fluoroethoxy)ethoxy)ethoxy)pyridinyl)vinyl)-N-methyl benzenamine (also known as
45, florbetapir-fluorine-, 8 or florbetapir), contains the longer-lasting radionuclide fluorine-18,
has recently been created, and tested as a possible diagnostic tool in Alzheimer's patients.
F10rbetapir, like PiB, binds to 13-amyloid, but due to its use of fluorine-, 8 has a half-life of 110
minutes, in contrast to PiB's radioactive half life of 20 minutes. It has also been found that the
longer life allowed the tracer to accumulate significantly more in the brains of the AD
patients, particularly in the regions known to be associated with beta-amyloid deposits.
There is therefore a need for further imaging agents which are capable of diagnosing
neurological disorders such as Alzheimer's disease.
Description of the Figures
Figure I shows the PET summation images (0-60 min) after administration of
compound (1)' in two rats.
Figure 2 shows the time-activity graphs in the brain of two rats (9'. administered dose
per grain brain) after administration of compound (1)'.
Detailed Description of the Invention
According to a first aspect of the invention, there is provided a radiolabelled glutaminyl
cyclase (QC) inhibitor for use as an imaging agent.
References herein to "radiolabelled" include a compound where one or more atoms are
replaced or substituted by an atom having an atomic mass or mass number different from the
atomic mass or mass number typically found in nature (i. e. , naturally occurring). One non-
limiting exception is ''F, which allows detection of a molecule which contains this element
without enrichment to a higher degree than what is naturally occurring. Compounds carrying
the substituent ''F may thus also be referred to as "labelled" or the like. The term
radiolabelled may be interchangeably used with "isotopically-labelled", nabelled", "isotopic
tracer group" "isotopic marker", "isotopic label", "detectable isotope" or "radioligand".
In one embodiment, the glutaminyl cyclase (QC) inhibitor comprises a single radiolabelled
group.
W0 21/12/163773
Examples of suitable, nori-limiting radiolabel groups include: 'H (D or deuterium), 'H (T or
tritium), ''c, ''C, ''C, ''N, ''N, ''0, ''0, ''0, ''F, ''S, ''c1,82Br, 75Br, 76Br, 77Br, 1231 1241 1251
and '''1. It is to be understood that an isotopically labeled compound needs only to be
enriched with a detectable isotope to, or above, the degree which allows detection with a
technique suitable for the particular application, e. g. in a detectable compound labeled with
''c, the carbon-atom of the labeled group of the labeled compound may be constituted by
''C or other carbon-isotopes in a fraction of the molecules. The radionuclide that is
incorporated in the radiolabelled compounds will depend on the specific application of that
radiolabelled compound. For example, for in vitro PIaque or receptor labelling and in
competition assays, compounds that incorporate 'H, tic, or '''1 will generally be most useful
For in vivo imaging applications ''c ''c ''F ''F '''1 '''1 '''1 ''Br, or ''Br will generally be
most useful. In one embodiment, the radiolabel is ''c. In an alternative embodiment, the
radiolabel is tic. In a yet further alternative embodiment, the radiolabel is roc.
In one embodiment, the glutaminyl cyclase (QC) inhibitor is a compound of formula (I
R2 X
IN, I
RI Y
or a pharmaceutical Iy acceptable salt, solvate or polymorph thereof, including all tautomers
and stereoisomers thereof wherein:
R represents heteroaryl, -carbocyclyl-heteroaryl, -C2-6alkenylheteroaryl, -Ci-6alkylheteroaryl,
or (CH2), CR'R'(CH2)bheteroaryl wherein a and b independently represent integers 0-5
provided that a + b = 0-5 and R' and R' are alkylene which together with the carbon to which
they are attached form a C3. C5 cycloalkyl group;
in which any of aforesaid heteroaryl groups may optionalIy be substituted by one or
more groups selected from Cj. 6alkyl, C2-6alkenyl, C2.6alkynyl, Ci-6haloalkyl, -Ci-
6thioalkyl, .SOCi4alkyl, -So2Ci4alkyl, Ci-6alkoxy-, C3^cycloalkyl, C3.8cycloalkyl,
So^C3-BCycloalkyl, -SOC, 6cycloalkyl, C3.6alkenyloxy-, C^., alkynyloxy-, -C(0)C, ., alkyl, -
C(0)0C, .6alkyl, C, ., alkoxy-CT6alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH2, -
NHC, 4alkyl, -N(CMalkyl)(C, 4alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH^,
C(0)NH(C, 4alkyl) and -C(0)NH(C3. ,, cycloalkyl);
PCT/EP2i112/1159649
W0 21/12/163773
and in which any of aforesaid carbocyclyl groups may optional Iy be substituted by one
or more groups selected from Cj4alkyl, oxo, halogen and CMalkoxy;
R' represents H, CT8alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -Gualkylaryl, -Ci_
4alkylheteroaryl, -Cj4alkylcarbocyclyl or -Cj4alkylheterocyclyl;
in which any of aforesaid aryl and heteroaryl groups may optional Iy be substituted by
one or more groups selected from Ci. 6alkyl, C2.6alkenyl, C2.6alkynyl, Ci. 6haloalkyl, -Cj_
6thioalkyl, -SOCi4alkyl, -So2Ci4alkyl, Ci-6alkoxy-, .0. C3. BCycloalkyl, C3. BCycloalkyl,
So2C^BCycloalkyl, -SOC^_6cycloalkyl, C3.6alkenyloxy-, C3_6alkynyloxy-, -C(0)C, .6alkyl, -
C(0)0C, _6alkyl, C, -6alkoxy-C, -salkyl-, C, ., alkoxy-Cj. 6alkoxy-, nitro, halogen, haloC, _
6alkyl, haloCi_6alkoxy, cyano, hydroxyl, -C(0)0H, -NH2, -NHC, 4alkyl, -N(C, ., alkyl)(Ci_
*alkyl), -N(C, 4alkyl)(C, 4alkyl)-N(CMalkyl)(C, 4alkyl), -C, 4alkyl-N(CMalkyl)(C, 4alkyl),
Cj4alkoxy-N(C, 4alkyl)(Cj4alkyl), -N(C3.8cycloalkyll)(C38cycloalkyl), -N(-C, 6alkyl-Cj.
,alkoxy)(-C, ., alkyl-C, .6alkoxy), -C(0)N(Cj. 4alkyl)(CMalkyl), -C(0)NH2, -C(0)NH(C, .
,alkyl) and -C(0)NH(C3. ,, cycloalkyl);
and in which any of aforesaid carbocyclyl and heterocyclyl groups may optional Iy be
substituted by one or more groups selected from C, .4alkyl, oxo, halogen, -C(0)Cj_6alkyl
and Cj4alkoxy;
or R' represents phenyl substituted by phenyl, phenyl substituted by a monocyclic heteroaryl
group, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl, phenyl
substituted by heterocyclyl wherein said heterocyclyl is substituted by phenyl, phenyl
substituted by CMalkyl-heterocyclyl, phenyl substituted by benzyloxy, phenyl
substituted by carbocyclyl, phenyl substituted by Garbocyclyl wherein said carbocyclyl
is substituted by heterocyclyl, phenyl substituted by carbocyclyl, heterocyclyl
substituted by phenyl, carbocyclyl substituted by phenyl, phenyl fused to carbocyclyl,
phenyl fused to heterocyclyl, -CMalkyl(phenyl substituted by phenyl), -C, 4alkyl(phenyl
substituted by a monocyclic heteroaryl group), -Cj4alkyl(phenyl substituted by a
monocyclic heterocyclyl group), -C, 4alkyl(phenyl substituted by an carbocyclyl
group), -C, 4alkyl(phenyl substituted by benzyloxy), -C, 4alkyl(optionalIy substituted
phenyl fused to optionalIy substituted carbocyclyl or -Ci4alkyl(optionalIy substituted
phenylfused to optionalIy substituted heterocyclyl);
in which any of aforesaid phenyl, benzyloxy and heteroaryl groups may optionalIy be
substituted by one or more groups selected from C, 4alkyl, halogen and C, 4alkoxy,
and in which any of aforesaid Garbocyclyl and heterocyclyl groups may optional Iy be
substituted by one or more groups selected from methyl, phenyl, oxo, halogen,
hydroxyl and Ct4alkoxy;
W0 21/12/163773
R represents H, -Cj4alkyl or aryl;
in which aforesaid aryl may optional Iy be substituted by one or more groups selected
from C, .6alkyl, C2.6alkenyl, C2.6alkynyl, Ci-6haloalkyl, -CISthioalkyl, .SOCi4alkyl,
So2Ci4alkyl, C, .6alkoXy-, C3-8cycloalkyl, C3-8cycloalkyl, -So2C3. BCycloalkyl, -SOC3.
6cycloalkyl, C3. ,alkenyloxy-, C^., alkynyloxy-, -C(0)C, .6alkyl, .C(0)0C, ., alkyl, C, .6alkoxy-
Ci_6alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH2, -NHC, 4alkyl, -N(Cj_
,alkyl)(C, 4alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH^, -C(0)NH(Gualkyl) and,
C(0)NH(C^_,, cycloalkyl);
or R' and R' are joined to form a carbocyclyl ring which is optionalIy substituted by one or
more Cj_2alkyl groups;
or R' and R' are joined to form a carbocyclyl ring which is fused to phenyl, wherein aforesaid
carbocyclyl and/or phenyl may optional Iy be substituted by one or more groups
selected from CMalkyl, halogen and Ci4alkoxy;
or R' and R' are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl,
wherein aforesaid carbocyclyl and/or heteroaryl may optional Iy be substituted by one or
more groups selected from Ci4alkyl, halogen and CMalkoxy;
X represents C=0,0, S, CR'R', CH2- or -CH2-CH2-;
Y represents CHR', C=O or C=S;
Z represents -N-R', O or CHR", such that when X represents O or S, Z must represent
CHRio.
or X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that
position and which is optional Iy substituted by one or more halogen or Cj_2alkyl groups;
R' represents H, -C, _8alkyl, -C(0)Ct_6alkyl or -NH2;
R' and R' independently represent H, -Cj4 alkyl or aryl;
in which said aforesaid aryl may be optional Iy substituted by Ci. 6alkyl, C2-6alkenyl, C2.
6alkynyl, Ci. 6haloalkyl, -Ci. 6thioalkyl, .SOCi4alkyl, .So2Ci. 4alkyl, Ci-6alkoxy. , .0. C3-
8cycloalkyl, C3.8cycloalkyl, -So2C3^cycloalkyl, .SOC3-6CyclOalkyl, C3.6alkenylOXy-, C3.
,alkynyloxy-, -C(0)CT6alkyl, -C(0)0C, ., alkyl, C, ., alkoxy-C, ., alkyl-, nitro, halogen,
cyano, hydroxyl, -C(0)0H, -NH2, -NHC, 4alkyl, -N(Gualkyl)(C, 4alkyl), -C(0)N(Cj.
,alkyl)(C, 4alkyl), -C(0)NH2, -C(0)NH(CMalkyl) and, -C(0)NH(C3_, 0cycloalkyl);
R' and R'' independently represent H or methyl;
provided that the inoiety -Y-Z-X- represents a inoiety other than -C(=0)-NCR')-C(. 0)- or
-C(=S)-NCR')-C(. 0)-.
Compounds of formula (1) are described in W0 2010/026212Al (Probiodrug AG)
W0 21/12/163773
In a further embodiment, the compound of formula (1) is I-(IH-benzo[d]jinidaz01y1)(4-
propoxyphenyl)jinidazolidin0ne:
I\,'
^ ^, O
(1),
The compound of formula (1)" is described as Example 12 in W0 2010/026212Al
(Probiodrug AG).
In a yet further embodiment, the compound of formula (1) is (S)-I-(IH-benzo[d]jinidaz01yl)-
-(4-propoxyphenyl)jinidazolidin0ne:
I\,, O
^^ .
(1)b
The compound of formula (1)' is described as Example 14 in W0 2010/026212Al
(Probiodrug AG).
In one embodiment, the radiolabelled compound is a compound of formula (1)':
W0 21/12/163773 PCT/EP21112/1159649
"^, O
'4, ;" I"' I "'
(1).
In one embodiment, the radiolabelled compound is a compound of formula (1)':
* position ''c. Label
I\./O
N , N~^'O
*,. I o
(1),
In one embodiment, the radiolabelled compound is a compound of formula (1)':
I'^HN
O ,30'
O\ I\ O, IC,
13 I
"'*C'
\j_:>,:o
(1).
In one embodiment, the radiolabelled compound is a compound of formula (1)':
W0 21/12/163773
I'=^^'HN
,, I'
HO, ,,,,;. C\,, I
,, 30 C
'<~,,, ' ,,,,
(1),
In one embodiment, the glutaminyl cyclase (QC) inhibitor is a compound of formula (
'I^a)n '
(11)
or a pharmaceutical Iy acceptable salt, solvate or polymorph thereof, including all tautomers
and stereoisomers thereof wherein:
R' represents -Cj. 6alkyl, -aryl, -Ci. 6alkylaryl, -cycloalKyl, -Ci. 6alkylcycloalkyl, -heteroaryl, .Ci.
6alkylheteroaryl, -heterocyclyl, -CT6alkylheterocyclyl, -cycloalkyl substituted by phenyl,
cycloalkyl substituted by phenoxy, -phenyl substituted by cycloalkyl, -phenyl substituted by
phenoxy, -phenyl substituted by phenyl, heterocyclyl substituted by phenyl, heteroaryl
substituted by phenyl, phenyl substituted by heterocyclyl, phenyl substituted by heteroaryl,
phenyl substituted by cycloalkyl or phenyl substituted by -cycloalkyl-heterocyclyl;
and in which any of aforesaid aryl, cycloalkyl, heterocyclyl, heteroaryl, phenyl or
phenoxy groups may optional Iy be substituted by one or more groups selected from
C, .Galkyl, C2.6alkenyl, C2. Balkynyl, C, .6haloalkyl, -Ci. 6thioalkyl, -SOCi. 4alkyl, -So2C, .
4alkyl, Ci. salkoxy-, C3. BCycloalkyl, C3. BCycloalkyl, -So2C3.8cycloalkyl, -SOC3.
,cycloalkyl, q_, alkenyloxy-, C3.6alkynyloxy-, -C(0)C, .6alkyl, -C(0)Oct. 6alkyl, Cj.
Balkoxy-Ci_6alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH2, -NHC, 4alkyl,
N(C, 4alkyl)(C, ., alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH2, -C(0)NH(Ct4alkyl) and -
C(0)NH(C, .,. cycloalkyl);
W0 21/12/163773 PCT/EP21112/(159649
R' represents -Cj. 6alkyl, Cj. 6haloalkyl, -aryl, -Cj. 6alkylaryl, -cycloalkyl, -Cj6alkylcycloalkyl, -
heteroaryl, -Cj. 6alkylheteroaryl, -heterocyclyl or -Cj_6alkylheterocyclyl;
and in which any of aforesaid aryl, heteroaryl or heterocyclyl groups may optional Iy be
substituted by one or more groups selected from Cj. 6alkyl, C2_6alkenyl, C2_6alkynyl, Ci-
6haloalkyl, .Ct-6thioalkyl, .SOCi4alkyl, -So2Ci4alkyl, Ci. 6alkoxy-, C3-8cycloalkyl, C3-
BCyCloalkyl, .So2C3.8CyCIOalkyl, -SOC3.6CyCIOalkyl, C3.6alkenylOXy-, C3.6alkynyloxy-,
C(0)C, ., alkyl, -C(0)0C, _, alkyl, C, _, alkoxy-C, _, alkyl-, nitro, halogen, cyano, hydroxyl, -
C(0)0H, -NH, , -NHC, 4alkyl, -N(Cj4alkyl)(C, 4alkyl), -C(0)N(C, 4alkyl)(C, 4a!kyl),
C(0)NH2, -C(0)NH(Gualkyl) and -C(0)NH(C3. IOCycloalkyl);
R' represents Ci. 6alkyl or Ci. 6haloalkyl;
n represents an integer selected from O to 3; and
R' represents Ct. 6alkyl, C2_6alkenyl, C2_6alkynyl, Ct_6haloalkyl, -Cj_6thioalkyl, -SOCj4alkyl,
So2Ci4alkyl, Ct-6alkoxy. , .0. C3. BCyCIOalkyl, C3-8cycloalkyl, -So2C3. BCycloalkyl, -SOC3-
,cycloalkyl, C3. Galkenyloxy-, C^., alkynyloxy. , .C(0)C, .6alkyl, .C(0)0C, -Galkyl, Ci-6alkoxy. C, -
,alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, ~NH2, -NHC, 4alkyl, -N(C, 4alkyl)(C, 4alkyl), -
C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH2, -C(0)NH(C, 4alkyl) and -C(0)NH(C^.,. cycloalkyl)
Compounds of formula (11) are described in W0 20/11/10613Al (Probiodrug AG)
In a further embodiment, the glutsminyl cyclase (QC) inhibitor is a compound of formula (1) or
formula (11) as hereinbefore defined.
In a further embodiment, the compound of formula (11) is I-(IH-Benzo[d]jinidaz01y1)(2,3-
difluoropheny1)methoxymethyl-IH-pyrr01-2(5H)-one:
\/ \.
' '' "\"' 1'
N~~:' '~\ I, ::
\ I\/ ~N' i''
H .>^'
(11),
The compound of formula (11)" is described as Example 8 in W0 20,111,0613Al (Probiodrug
AG).
W0 21/12/163773
In a further embodiment, the compound of formula (11) is (R)~I-(I H-Benzo[d]jinidaz01y1)
(2,3-dimoropheny1)methoxymethyl-I H-pyrr01-2(5H)-one:
<.'1N
(11).
The compound of formula (11)' is described as Example 9 in W0 20,111,0613A, (Probiodrug
AG).
In one embodiment, the radiolabelled compound is a compound of formula (11)':
(11).
In a further embodiment, the radiolabelled compound is a compound of formula (11)':
W0 21/12/163773 PCT/EP21112/1159649
(11),
In one embodiment, the glutaminyl cyclase (QC) inhibitor is a compound of formula (111):
(111)
or a pharmaceutical Iy acceptable salt, solvate or polymorph thereof, including all tautomers
and stereoisomers thereof wherein:
R' represents -C3.8carbocyclyl. heteroaryl, -C2.6alkenylheteroaryl, -Ci. 6alkylheteroaryl, or
(CH2), CR'R'(CH2)bheteroaryl wherein a and b independently represent integers 0-5 provided
that a + b = 0-5 and R' and R' are alkylene which, together with the carbon to which they are
attached, form a C3-C5 cycloalkyl group, or a bicyclic heteroaryl group;
in which any of aforesaid heteroaryl groups may optional Iy be substituted by one or
more groups selected from Ci. 6alkyl, C2.6alkenyl, C2-6alkynyl, Cj_6haloalkyl, -Ci-
6thioalkyl, -SOCj4alkyl, -So2Ci4alkyl, Ci_6alkoxy-, C3.8cycloalky!, C3.8cycloalkyl,
So2C3.8CyCloalkyl, .SOC3.6CyCIOalkyl, C3_6alkenyloxy. , C3.6alkynylOxy-, -C(0)Cj_6alkyl, -
C(0)0C, _6alkyl, C, ., alkoxy-C, _Galkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH, , -
NHC, 4alkyl, -N(CMalkyl)(C, ., alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH^,
C(0)NH(C, 4alkyl) and -C(0)NH(q_, ocycloalkyl);
and in which any of aforesaid carbocyclyl groups may optional Iy be substituted by one
or more groups selected from Cj4alkyl, oxo, halogen and CMalkoxy;
PCT/EP21112/(159649
W0 21/12/163773
R' represents Ct_8alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -Cj4alkylaryl, -Cj_
4alkylheteroaryl, -CMalkylcarbocyclyl or -Ct4alkylheterocyclyl;
in which any of aforesaid aryl and heteroaryl groups may optional Iy be substituted by one or
more groups selected from Ci-6alkyl, C2-6alkenyl, C2.6alkynyl, Ci-6haloalkyl, -Cj. 6thioalkyl,
.SOCi4alkyl, .So2Ci4alkyl, Ci-6alkoxy. , .0. C3.8cycloalkyl, C3.8cycloalkyl, .So2C3.8cycloalkyl,
-SOC^., cycloalkyl, C, ., alkenyloxy-, C3. ,alkynyloxy-, -C(0)C, .6alkyl, -C(0)0C, -6alkyl,
C, ., alkoxy-C, ., alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH^, -NHC, 4alkyl,
-N(C, 4alkyl)(Cj4alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NHz -C(0)NH(C, 4alkyl) and
-C(0)NH(C3_, 0cycloalkyl);
and in which any of aforesaid carbocyclyl and heterocyclyl groups may optionalIy be
substituted by one or more groups selected from Cj4alkyl, oxo, halogen and Ci. 4alkoxy;
or R' represents phenyl substituted by phenyl, phenyl substituted by a monocyclic heteroaryl
group, phenyl substituted by benzyloxy, phenyl fused to carbocyclyl, phenyl fused to
heterocyclyl, -C, 4alkyl(phenyl substituted by phenyl), -CMalkyl(phenyl substituted by a
monocyclic heteroaryl group), -C, 4alkyl(phenyl substituted by benzyloxy), -C, .
4alkyl(optionalIy substituted phenyl fused to optionalIy substituted carbocyclyl or -Ct.
,alkyl(optionalIy substituted phenylfused to optionalIy substituted heterocyclyl);
in which any of aforesaid phenyl, benzyloxy and heteroaryl groups may optional Iy be
substituted by one or more groups selected from Cj4alkyl, halogen and Cj4alkoxy,
and in which any of aforesaid Garbocyclyl and heterocyclyl groups may optionalIy be
substituted by one or more groups selected from Cj4alkyl, oxo, halogen and CMalkoxy;
R represents H, -Cj4alkyl or aryl;
in which aforesaid aryl may optionalIy be substituted by one or more groups selected
from Ci. 6alkyl, C2.6alkenyl, C2. Galkynyl, Ci-6haloalkyl, .Ci. 6thioalkyl, -SOCi4alkyl,
So2Ci4alkyl, Ci-6alkoxy-, ~0. C3. BCycloalkyl, C3.8cycloalkyl, -So2C3.8cycloalkyl, -SOC3-
6cyclOalkyl, C3.6alkenylox^, C^.^alkynyloxy-, -C(0)C, .6alkyl, .C(0)0C, -6alkyl, Ci-6alkOXy-
C, .6alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)0H, -NH2, -NHC, 4alkyl, -N(C, .
^alkyl)(C, 4alkyl), -C(0)N(C, 4alkyl)(C, 4alkyl), -C(0)NH^, -C(0)NH(C, 4alkyl) and,
C(0)NH(C3_, 0cycloalkyl);
or R' and R' are joined to form a carbocyclyl ring which is optionalIy substituted by one or
more C, _2alkyl groups;
or R' and R' are joined to form a carbocyclyl ring which is fused to phenyl, wherein aforesaid
carbocyclyl and/or phenyl may optional Iy be substituted by one or more groups
selected from Ct4alkyl, halogen and Cj. 4alkoxy;
W0 21/12/163773 PCT/EP21i12/1159649
or R' and R' are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl,
wherein aforesaid carbocyclyl and/or heteroaryl may optionalIy be substituted by one or
more groups selected from Ci4alkyl, halogen and Cj4alkoxy;
R' represents H, -C, ."alkyl, -C(0)C, ., alkyl or -NH^;
X represents O or S; and
Y represents O or S.
Compounds of formula (111) are described in GB Patent Application No. 1003936.0
(Probiodrug AG).
In one embodiment, the radiolabelled glutaminyl cyclase (QC) inhibitor is a compound of
formula (IV):
S \ 'CH
I 11CH3
I'N""'N o
(IV)
In one embodiment, the radiolabelled glutaminyl cyclase (QC) inhibitor is a compound of
formula 01)'
, 0,
o \ 'CH
I ICH3
I' N I"' N
Processes for incorporating the radiolabels into the glutaminyl cyclase (QC) inhibitors may be
carried outin accordance with known labelling procedures. For example, W0 2010/11/303
describes the process of labelling compounds with an 18-fluorine isotope.
For example, the compound of formula (IV) may be prepared in accordance with the process
shown in Scheme A
W0 21/12/163773
I'N""NH
o CH3
; ---.,-I \ -
I ICH3 I'N"v"'N OH
/3
I'N"V"N
''cH
ICH3
I ICH3
I'N""N o
I'~ N I"' N
''cH3
Scheme A
Furthermore, the compound of formula (V) may be prepared in accordance with the process
shown in Scheme B:
W0 2/1/21163773
OH o
I ICH3
HO HO OH
ICH3
o I'~N N OH
I'~N"/'N
.^..
ticH
ICH3
I ICH3
I'N N o
I' N"^" N
''cH3
Scheme B
In one embodiment, the inhibitor as defined herein is used as a medical imaging agent. In a
further embodiment, the inhibitor as defined herein is used as a medical imaging agent in the
detection of a neurological disorder.
According to a further aspect of the invention, there is provided a pharmaceutical
composition comprising a radiolabelled compound as defined herein or a pharmaceutical Iy
acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers
thereof, in combination with one or more pharmaceuticalIy acceptable excipients.
PharmaceuticalIy acceptable salts:
In view of the close relationship between the free compounds and the compounds in the form
of their salts or solvates, whenever a compound is referred to in this context, a corresponding
salt, solvate or polymorph is also intended, provided such is possible or appropriate under
the circumstances.
PCT/EP21i12/(159649
W0 21/12/163773
Salts and solvates of the glutaminyl cyclase (QC) inhibitors and physiologically functional
derivatives thereof which are suitable for use in medicine are those wherein the counter-ion
or associated solvent is pharmaceuticalIy acceptable. However, salts and solvates having
non-pharmaceuticalIy acceptable counterions or associated solvents are within the scope of
the present invention, for example, for use as intermediates in the preparation of other
compounds and their pharmaceuticalIy acceptable salts and solvates.
Suitable salts according to the invention include those formed with both organic and
inorganic acids or bases. Pharmaceutical Iy acceptable acid addition salts include those
formed from hydrochloric, hydrobromic, sulfuric, nitric, citric, tartaric, phosphoric, lactic,
pyruvic, acetic, trifluoroacetic, triphenylacetic, sulfamic, sulfanilic, succinic, oxalic, fumaric,
maleic, in alic, inaridelic, glutamic, aspartic, oxaloacetic, methanesulfonic, ethanesulfonic,
arylsulfonic (for example p-toluenesulfonic, benzenesulfonic, naphthalenesulfonic or
naphthalenedisulfonic), salicylic, glutaric, 91uconic, tricarballylic, cinnamic, substituted
cinnamic (for example, phenyl, methyl, methoxy or halo substituted cinnamic, including 4-
methyl and 4-methoxycinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for
example I- or 3-hydroxynaphthoic), naphthaleneacrylic (for example naphthalene
acrylic), benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-
phenylbenzoic, benzeneacrylic (for example I, 4-benzenediacrylic), isethionic acids,
perchloric, propionic, glycolic, hydroxyethanesulfonic, painoic, cyclohexanesulfamic, salicylic,
saccharinic and trifluoroacetic acid. Pharmaceutical Iy acceptable base salts include
ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth
metal salts such as those of calcium and magnesium and salts with organic bases such as
dicyclohexylamine and N-methyl-D-91ucamine.
All pharmaceutical Iy acceptable acid addition salt forms of the compounds of the present
invention are intended to be embraced by the scope of this invention.
Polymorph crystal forms:
Furthermore, some of the crystalline forms of the compounds may exist as polymorphs and
as such are intended to be included in the present invention. In addition, some of the
compounds may form solvates with water (i. e. hydrates) or common organic solvents, and
such solvates are also intended to be encompassed within the scope of this invention. The
compounds, including their salts, can also be obtained in the form of their hydrates, or
include other solvents used for their crystallization.
W0 2/1/21163773 PCT/EP21112/1159649
PharmaceuticalIy acceptable excipients:
Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions,
suitable carriers and additives may advantageously include water, glycols, oils, alcohols,
flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such
as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives
include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating
agents and the like.
Carriers, which can be added to the mixture, include necessary and inert pharmaceutical
excipients, including, but not limited to, suitable binders, suspending agents, lubricants,
flavorants, sweeteners, preservatives, coatings, disintegrating agents, dyes and coloring
agents.
Soluble polymers as targetable drug carriers can include polyvinylpyrrolidone, pyran
copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamide-phenol,
or polyethyleneoxidepolyllysine substituted with palmitoyl residue. Furthermore, the
compounds of the present invention may be coupled to a class of biodegradable polymers
useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon
caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans,
polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or
betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or
sodium o1eate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate,
sodium chloride and the like.
Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan
gum and the like.
According to a further aspect of the invention, there is provided the pharmaceutical
composition as defined herein, for use as an imaging agent in the detection of a neurological
disorder.
W0 21/12/163773
Examples of suitable non-limiting neurological disorders include: mild cognitive impairment,
Alzheimer's disease, Familial British Dementia, Familial Danish Dementia,
neurodegeneration in Down Syndrome and Huntington's disease. In one particular
embodiment, the neurological disorder is Alzheimer's disease.
In one embodiment, the inhibitor or composition of the invention is used in the detection of
amyloid peptides.
In one embodiment, the inhibitor or composition of the invention is used in the detection of
tau proteins of neurofibrillary tangles.
The detection of such amyloid peptides has utility in the detection and quantification of
amyloid deposits and/or neurofibrillary tangles in diseases including, but not limited to
Mediterranean fever, MuckleWells syndrome, idiopathetic myeloma, amyloid polyneuropathy,
amyloid cardiomyopathy, systemic senile my10idosis, amyloid polyneuropathy, hereditary
cerebral hemorrhage with amyloidosis, Down's syndrome, Scrapie, Creutzfeldt-Jacob
disease, Kuru, Gerstamnn-Straussler-Scheinker syndrome, medullary carcinoma of the
thyroid, Isolated atrial amyloid, [beta]2-microglobulin amyloid in dialysis patients,
inclusionbody myositis, 132-amyloiddeposits in muscle wasting disease, chronic traumatic
encephalopathy (CTE), and Islets of Langerhans diabetes Type 11 insulinoma
The radiolabelled compounds of the invention may be administered by any means known to
the person skilled in the art. For example, administration may be local or systemic and
accomplished orally, parenterally, by inhalation spray, topicalIy, rectalIy, inhaled, nasalIy,
buccally, vaginalIy, or via an implanted reservoir. The term "parenteral" as used herein
includes subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal,
intraventricular, intrasternal, intracranial, and intraosseous injection and infusion techniques.
Dose levels can range from about 0,001 Fig/kg/day to about 10,000 ing/kg/day. In one
embodiment, the dose levelis about 0001 Fig/kg/day to about 10 91kg/day. In another
embodiment, the dose level is about 0.01 Fig/kg/day to about 1.0 g/kg/day. In yet another
embodiment, the dose level is about 0.1 ing/kg/day to about I 00 ing/kg/day.
The exact administration protocol and dose levels will vary depending upon various factors
including the age, body weight, general health, sex and diet of the patient; the determination
W0 21/12/163773 PCT/EP21112/1159649
of specific administration procedures would be routine to any one of ordinary skill in the art.
The regimen may include pre-treatment and/or co-administration with additional compounds
such as for example therapeutic agent(s).
According to a further aspect of the invention there is provided a method for imaging and
detection of senile PIaques and/or neurofibrillary tangles in a brain tissue, the method
comprising treating the tissue with an inhibitor as defined herein for detection of neurological
disorders.
In one embodiment, the neurological disorder is detected by measuring the affinity of an
inhibitor as defined herein for senile piaques.
In one embodiment, the neurological disorder is detected by measuring the affinity of an
inhibitor as defined herein for tau aggregates.
According to a further aspect of the invention there is provided a method for ex vivo or in vitro
detection of amyloid deposits in a brain tissue, the method comprising treating the tissue with
an inhibitor as defined herein for detection of the amyloid deposit.
According to a further aspect of the invention there is provided a method for in vivo detection
of amyloid deposits in a patient, the method comprising administering an effective amount of
an inhibitor as defined herein to the patient, and detecting the binding level of the compound
to the amyloid deposit to the patient.
According to a further aspect of the invention there is provided a method for ex vivo or in vitro
detection of tau proteins in a brain tissue, the method comprising treating the tissue with an
inhibitor as defined herein for detection of the neurofibrillary tangles.
According to a further aspect of the invention there is provided a method for in viVo detection
of neurofibrillary tangles in a patient, the method comprising administering an effective
amount of an inhibitor as defined herein to the patient, and detecting the binding level of the
compound to tau proteins.
In one embodiment, the method relates to detecting senile PIaques and neurofibrillary
tangles characteristic for a neurological disorder.
PCT/EP21i12/1159649
W0 21/12/163773
In one embodiment, the detection is performed using gamma imaging, magnetic resonance
imaging, magnetic resonance spectroscopy or fluorescence spectroscopy.
In one embodiment, the detection by gamma imaging is PET or SPECT. Positron Emission
Tomography (PET) is a precise and sophisticated technique using isotopes produced in a
cyclotron. A positron-emitting radionuclide is introduced, usually by injection, and
accumulates in the target tissue. As it decays it emits a positron, which promptly combines
with a nearby electron resulting in the simultaneous emission of two identifiable gamma rays
in opposite directions. These are detected by a PET camera and give very precise indication
of their origin. PET's most important clinical role is in oncology, with fluorine-18 as the tracer,
since it has proven to be the most accurate nori-invasive method of detecting and evaluating
most cancers.
It is also well used in cardiac and brain imaging.
A number of medical diagnostic procedures, including PET and SPECT utilize radiolabeled
compounds, are well known in the art. PET and SPECT are very sensitive techniques and
require small quantities of radiolabeled compounds, called tracers. The labeled compounds
are transported, accumulated and converted in vivo in exactly the same way as the
corresponding non-radioactiveIy compound. Tracers, or probes, can be radiolabeled with a
radionuclide useful for PET imaging, such as ''c, ''N, ''0, ''F, 'CU and '''1, or with a
radionuclide useful for SPECT imaging, such as ''Tc ''Br ''Cu '''Gd '231 1251 13/1 and 32p.
PET creates images based on the distribution of molecular imaging tracers carrying positron-
emitting isotopes in the tissue of the patient. The PET method has the potential to detect
malfunction on a cellular level in the investigated tissues or organs. PET has been used in
clinical oncology, such as for the imaging of tumors and metastases, and has been used for
diagnosis of certain brain diseases, as well as mapping brain and heart function. Similarly,
SPECT can be used to complement any gamma imaging study, where a true 30
representation can be helpful, for example, imaging tumor, infection (leukocyte), thyroid or
bones.
The person skilled in the art is familiar with the various ways to detect labeled compounds for
imaging purposes. For example, positron emission tomography (PET) or single photon
emission computed tomography (SPECT) can be used to detect radiolabeled compounds.
The label that is introduced into the compound can depend on the detection method desired.
W0 2/1/21163773 PCT/EP21112/1159649
The person skilled in the art is familiar with PET detection of a positron-emitting atom, such
as F. The present invention is also directed to specific compounds described herein where
the F atom is replaced with a non-radiolabeled fluorine atom. The person skilled in the art is
familiar with SPECT detection of a photon-emitting atom, such as '''1 or ''Tc.
The radiolabelled glutaminyl cyclase inhibitor of the invention should typically have sufficient
radioactivity and radioactivity concentration to assure reliable diagnosis. The imaging of
amyloid deposits and neurofibrillary tangles can also be carried out quantitative Iy so that the
amount of amyloid deposits and neurofibrillary tangles can be determined.
One of the key prerequisites for an in vivo imaging agent of the brain is the ability to cross
the intact blood-brain barrier after a bolus i. v. injection. In the first step of the present method
of imaging, the radiolabelled glutaminyl cyclase inhibitor of the invention is introduced into a
tissue or a patient in a detectable quantity. The compound is typically part of a
pharmaceutical composition and is administered to the tissue or the patient by methods well
known to those skilled in the art.
In an alternative embodiment, the radiolabelled glutaminyl cyclase inhibitor of the invention is
introduced into a patient in a detectable quantity and after sufficient time has passed for the
compound to become associated with amyloid deposits and/or tau proteins, the labeled
compound is detected nori-invasive Iy. In another embodiment of the invention, the
radiolabelled glutaminyl cyclase inhibitor of the invention is introduced into a patient,
sufficient time is allowed for the compound to become associated with amyloid deposits, and
then a sample of tissue from the patient is removed and the radiolabeled compound in the
tissue is detected apart from the patient. In another embodiment of the invention, a tissue
sample is removed from a patient and a radiolabelled glutaminyl cyclase inhibitor of the
invention is introduced into the tissue sample. After a sufficient amount of time for the
compound to become bound to amyloid deposits and/or tau proteins, the compound is
detected.
A detectable quantity is a quantity of labeled compound necessary to be detected by the
detection method chosen. The amount of radiolabelled glutaminyl cyclase inhibitor of the
invention to be introduced into a patient in order to provide for detection can readily be
determined by those skilled in the art. For example, increasing amounts of the radiolabeled
compound can be given to a patient until the compound is detected by the detection method
W0 21/12/163773
of choice. A label is introduced into the compounds to provide for detection of the
compounds.
The amount of time necessary can easily be determined by introducing a detectable amount
of radiolabelled glutaminyl cyclase inhibitor of the invention into a patient and then detecting
the radiolabeled compound at various times after administration.
According to a further aspect of the invention there is provided a kit for diagnosing a
neurological disorder which comprises a pharmaceutical composition as defined herein and
instructions to use said kit in accordance with the methods described herein.
^!^^.
^!^:.
Pre aration of Benzimidazole''C Coin ound of Formula I ' Coin ound of
intermediate 7
I 'Y'\
(i) NaOH, H20
H2N N
N N\
I I^cH
\\ CT^
I N 2HCl
"' , 0.1\
H .2HCl
O~ I
Me3SiCN, ACOH
room temperature
To 5-amino[2. 'C]benzimidazole dihydrochloride (1.30 g, 6.27 mm01,375 inci) was added
water (10 inI) followed by 2 M sodium hydroxide solution (6.3 inI, 12.60 minol). The mixture
was stirred for 5 minutes at room temperature then the solvent was removed under reduced
pressure. Acetic acid (6.2 in I) was added to the residue and the slurry was stirred at room
temperature. Next, 4-propoxybenzaldehyde (935 ing, 5.69 mmol) was added dropwise over
minutes. Also, trimethylsilyl cyanide (846 ing, 8.52 minol) was added dropwise over 15
minutes and the reaction mixture was stirred for 3 hours at room temperature under an
atmosphere of nitrogen gas.
The reaction mixture was added dropwise to ice cold 28% ammonium hydroxide solution
(15ml) with stirring. The product was extracted into ethyl acetate (3 x 20 in I) and the extracts
W0 20/2/163773 PCT/EP21112/1159649
were combined. After drying over sodium sulphate, the slurry was filtered and the solvent
was removed under reduced pressure. The product was purified by flash chromatography
and the required fractions were combined. The solvent was removed under reduced
pressure and the remaining solid was pumped under vacuum to constant weight to give the
title compound (1.67 g, 5.22 min01,312 inci).
intermediate 2
I ',,'\
N, N \
H2I 10% Pd/C
ACOH
Hi4c' I
room temperature
N NH*
H NHz
To Intermediate I (267 ing, 0.84 min01,50.0 inci) was added a slurry of 109', palladium on
carbon, Degussa type EIOI R/W (51mg) in acetic acid (3 in I) under an atmosphere of
nitrogen gas. The mixture was stirred under hydrogen gas at room temperature for 18 hours'
The catalyst was removed by filtration through a pad of Gelite then washed with acetic acid
(10 in I). The filtrate was evaporated to dryness under reduced pressure and toluene (20 in I)
was added to the residue. The solvent was removed under reduced pressure which gave the
title compound (0.75 minol, equivalent to 45 inci).
18enzimidazole''Cj Compound of Formula (1)"
^>..
TEA, CDl, THF
reflux
\\ O
To Intermediate 2 (0.75 min01,45 inci) was added tetrahydrofuran (2.8 in I), triethylamine
(227 ing, 2.25 mmol) and 1.1-carbonyldiimidazole (146 ing, 0.90 mmol). The reaction mixture
was stirred at 85 'C for 2 hours,
W0 21/12/163773
After cooling to room temperature, water (15 in I) was added and the product was extracted
into ethyl acetate (3 x 20 in I). The extracts were combined, washed with saturated sodium
chloride solution (, O inI) then dried over sodium sulfate. The slurry was filtered and the
solvent was removed under reduced pressure.
The product was purified by reverse phase high performance liquid chromatography. The
required fractions were combined and the organic solvent was removed under reduced
pressure. To the remaining aqueous phase was added saturated sodium chloride solution
(15 inI) and the product was extracted into ethyl acetate (2 x 15 inI). The extracts were
combined and the solvent was removed under reduced pressure. This gave the title
compound (0,098 minol, equivalent to 5.9 inci).
IBenzimidazole''Cj Compound of Formula (1)'
^.^>..
Chiral chromatography
\,\ O
(1).
The tbenzimidazole-2. 'CI Compound of Formula (1)' (0,098 minol, equivalent to 5.9 inci)
was dissolved in n-heptane:ethanol:methanol:diethylamine (500:250:250:5; 5ml) and the
isomers were resolved by chiral high performance liquid chromatography using a Pirkle
Whelk column.
The required fractions were combined and the solvent was removed under reduced
pressure. The remaining residue was dissolved in acetonitrile:water (33:66; 5 inI) then
Iyophilised to give a solid, which was pumped to hard vacuum and constant weight. This
gave the title compound (14.0 ing, 0.0415 min01,2.49 inci).
Technical Data:
Specific Activity
Determined by:
W0 2/1/21163773
PCT/EP21112/(159649
61 inci/minol
Mass Spectrometry 2.26 GBq/mmol
Gravimetric Analysis 178 PCi/ing
6.59 MBq/ing
60 inci/mmol
Equivalent to 2.22 GBq/minol
338.3
Molecular Weight (at this specific activity):
Radiochemical Purity at HPLC: 99.9%
Column
Phenomenex Luna C18(2) 150 x 4.6 min
ambient
Temperature:
Solvent A 0.05% trifluoroacetic acid in water
Solvent B: 0,059', trifluoroacetic acid in acetonitrile
Gradient 15 20 21 30
Time (min) O
91, B o 100 100 O o
Flow Rate: I .O in 11min
UV Detection: 254 rim
Chemical Purity by HPLC: 99.0%
Column
Phenomenex Luna C18(2) 150 x 4.6 mm
ambient
Temperature:
0,059', trifluoroacetic acid in water
Solvent A
Solvent B : 0.05% trifluoroacetic acid in acetonitrile
Gradient: 15 20 21 30
Time (min) O
%B o 100 100 O o
Flow Rate I .O in 11min
UV Detection: 254 rim
Chiral Purity by HPLC: > 99.9%
Column:
Regis Pirkle Whelk 02 (R, R) 250 x 4.6 mm lopm
ambient
Temperature
Solvent:
n-heptane:ethanol:methanol:diethylamine (50:25:25:0.5)
ISOCratic for 30 minutes
Gradient:
Flow Rate I D in 11min
W0 2/1/21163773
Pre aration of Benzimidazole''C Coin ound of Formula I Coin ound of
I 'clc02
I) LiEtaBHITHF
I\, O \ I'..,-0 , Position C-Label
I ') H20
NII NH
I ClHcoOH
N \N~/
H2N , N^:
2N aq. HCl *<11 ^
140'C 10 min
(1),
["C]CO2 was introduced in loopl THF and 50pl LiEt3BH in the reactor vessel at -20'C. After
a reaction time of 40s, hydrolysis was performed by adding 5001, I H20. As reaction product,
[, I']HCOOH was obtained.
Thereafter, (S)-I-(3,4-diaminopheny1)-5<4-propoxyphenyl)jinidazolidinone (ling in 300pl
2N aq. HCl) was added. After a reaction time of 10 min. at 140'C, the reaction mixture was
cooled down and the product was purified by HPLC
Column:
Chromolith Performance RP-18 endcapped 100 - 4.6 mm monolithic HPLC-
column (MERCK)
1.5 Solvent:
I69", Acetonitrile in H^0 (0.1% TFA)
Flow rate: 6 in 11min
(S)-I-(3,4-diaminopheny1)(4-propoxyphenyl)jinidazolidin0ne: 3-7 min;
compound (1)': 8-9.5 min
The product peak containing compound (1)' was collected in I 00ml H20 and for further
purification loaded onto a SepPak tc18 column. The SepPak tc18 column was washed with
IOml H20. Compound (1)' was then eluted with 3ml ethanol. Thereafter the product was dried
at 96'C in an argon atmosphere
The final tracer solution was obtained by dissolving compound (1)' in loopl ethanol under
addition of NaCl (final concentration of ethanol max. 109',)
Specific Activity: 35,7 GBqi",, in o1
StabMty' of final tracer solution after 7.5 hours at room temperature: >98% to=6)
W0 21/12/163773 PCT/EP21112/(159649
Technical data:
Analytical HPLC
HPLC:
Agilent HP1200 DAD incl. Autosampler and Raytest RA detector (BGO cell)
Column:
Chromolith Performance RP-18 endcapped 100 - 4.6 mm monolithic HPLC-
column (MERCK)
Solvent: A 0.1% TFAin H20
B: Acetonitrile
I in 11min
Flow rate:
Onomin: 15-20% B
Gradient
-24min: 20-50% B
24-26min: 50-959'. B
26-27min: 95% B
27-28min: 15% B
28-30min: 15% B
Equilibration: 8min: 159', B (prior to injection)
UV Detection: 225nm
Analytical HPLC - Chiral Method
HPLC:
Agilent HPllOO DAD incl. Raytest RA Detector (PET)
Column:
Chiralcel OD-H (ODHOCE-PA130) 4.6x250mm + 4,5xlOmm
incl precolumn
Solvent: n-Hexane/ethanol80/20
Flow rate : jinl/min
UV detection: 225nm
Pre aration of I- IH-Benzimidaz01 I 4- ro ox heri I- ''C6 -jinidazolidin0ne
Coin ound of Formula I '
intermediate I: Propoxybenzene-!"Cal
W0 21/12/163773
NaOH, DMSO,
13 PI ~, s
iodopropane
"'31 ,, 3<3
BC "C
,S *
BC ''c
C\ f:::^!=
', s <:::"
Phenol-["CG] (1.20 g, 12.0 mmol) was dissolved in DMS0 (12 inI). Finely powdered sodium
hydroxide (1.9 g, 48 minol) was added, and was allowed to stir briskly at room temperature
for I5 min. 10dopropane (4.08 g, 24.0 minol) was then added dropwise over 3 min, and the
reaction mixture stirred for 30 min. The reaction was sampled for a mini workup, and
analysed by GC-Ms. A single peak at 6.3 min (in/z 142) indicated the reaction was complete,
and was worked up by addition to chilled water (100 in I). The quenched reaction was
extracted with hexanes (4 x 25 in I), pooled and washed in succession with a dilute sodium
hydroxide solution and with brine. The organic extract was dried with sodium sulphate,
filtered, and solvent removed in vacuo to give a syrupy product (1.4 g, 9.9 min01,82%). The
reaction was repeated using 1.6 g phenol-["C6] (16 mmol)in a similarfashion to provide 1.50
g (10.6 min01, 6691, ) which was combined with the above preparation. The pooled title
compound was used in the subsequent step without additional purification.
intermediate 2: 7-8rom0propoxybenzene-1''c, j
./ .I
acetonitrile, 13
,3 1' ~, a
NBS, NH N03
'SGI ' '3<3 "C ~ "C
,S ,
"C "C
C*., s <5:^C C\ ,:::;. C
B, '
To Intermediate I (2.76 g, 19.4 mmol) dissolved in acetonitrile (15 in I) was added ammonium
nitrate (0.15 g, 1.9 min01,0.1 eq, ACS grade) and stirred for 10 min. N-bromosuccinimide
(3.42 g, I 9.2 min01, 0.99 eq, recrystallized from water) was added and stirred at room
temperature for 30 min. Analysis by GC-Ms confirmed the consumption of starting material
and indicated a new product peak containing bromine at 10.8 min (in/z 220+222). The
W0 21/12/163773 PCT/EP21112/1159649
reaction was quenched in 50 in I and 50 in I hexanes. After extraction of the aqueous with
additional ethyl acetate-hexanes (I :I, 4 x 25 in I), the pooled organic layers were washed
with water followed by brine, then dried with sodium sulfate. Filtration and evaporation of
solvent gave the title compound (4.2 g, 19 mm01,9891, ) which was used in the subsequent
step without additional purification.
intermediate 3: 4-Propoxybenzaldehyde-1''C6j
13 I' '13
IC 'c
130 130
C, ,^. C
n-BULi, THF. -78C
---^. ,, I
To Intermediate 2 (4.0 g, 18 mmol) in dry THF (, 6 inI) at -78'C under an inert atmosphere
was added n-butyllithium solution (2.5 M in hexanes, 10.9 inI, 27.1 min01,1.5 eq) over 5 min.
This cold mixture was stirred for an additional 75 min. A solution of dry DMF (2.6 g, 36 minol,
2 eq) in dry THF 06 inI) was then added slowly, and the reaction was stirred for 2.5 h as the
cooling bath warmed to O'C. GC-Ms analysis then indicated the reaction was complete with
product found at 11.5 min (in/z 170). The reaction was quenched in cold dilute citric acid and
extracted with methyl ten-butylether-hexane (I :, , 4 x 25ml). Pooled extracts were washed
with water (2 x 25 in I), then brine (25 in I), and dried with sodium sulfate. Filtration and
evaporation of solvent gave 3.5 g crude product. This crude product was purified on silica
using ethyl acetate-hexanes (7.5:92.5) to give 2.83 g of the title compound (16.6 mmol,
929',).
intermediate 4: I(IH-Benzimidaz01ylamin0)I-(4-propoxypheny1-1''C6j)acetonitrile
PCT/EP21)12/1/59649
W0 20/2/163773
O ,3C
', 3 C"' '13
,3c/ 13c
13 I ', a
13c '30
13 13
C, IC
', 3 <:"' ^.
Satinoberizan, dazole,
'1e, """'c ;'11-."" I '
mirethylsilylcyanide
.,. I
acetic acid
Intermediate 3 (2.0 g, I 1.8 minol) was added to a solution of 5-aminobenzimidazole (1.73 g,
13.0 min01,1.1 eq) in acetic acid (14 inI) and stirred for 15 min. Trimethylsilylcyanide (2.3 inI,
1.8 g, 18 minol) was added dropwise over 15 min, and the resulting dark reaction solution
was stirred for 3 h at room temperature. Reaction progress was monitored by TLC
(methanol-chloroform, 10:90) and Ms. Reaction mixture was quenched by addition to cold
% ammonium hydroxide (35 in I). The resulting solid product was retained and dissolved in
ethyl acetate, and the aqueous mixture was further extracted using ethyl acetate (3 x 25 in I).
The pooled organic solutions were washed with water (2 x 25 in I), then brine (25 in I), dried
with sodium sulfate, filtered and evaporated to give crude product which was used in the
subsequent step without additional purification.
In termedia te 5:
N'-(iH-Benzimidaz01y41-I-(4-propoxypheny1-1'Cof)ethane-7,2-
diamine
O 13C
O, IC,
'13 ':::"' ', 3
13c 3c
,, I, ,,^ ^ H
Cc. IC N
~ "C '~
Pd-c H I
Pd-C, H2 I N
acetic acid t
,. 5
W0 21/12/163773
The crude product of Intermediate 4 was dissolved in acetic acid (40 in I) and was
hydrogenated using Pd-carbon (10%, 0.8 g) and 40 psi hydrogen for 24 h. Filtration on Gelite
and evaporation of solvent yielded IO g syrupy product. TLC (methanol-chloroform 10:90,
Rf=0) and Ms(+) (in/z 317) confirmed the reaction was complete. The crude product was
purified on a silica column using methanol-dichloromethane-methylamine (2 L, I 0:90:0.1 ),
then methanol-dichloromethane-methylamine (1.2 L, 20:80:0.1) to give 2.9 g of the title
compound (9.2 mm01,789',) over two steps
7-(IH-Benzimidaz01y!)y"propoxypheny1-1''Caj-jinidazo"din0ne
(Compound of Formula (411)
O ,sC'
o, ,,?. C,
CDl, TEA, THF 13 13
', 3I'
\I. .:>,=o
(1),
To a solution of triethylamine (1.28 g, 12.6 mm01,4 eq) and I, ,'-carbonyldiimidazole (CDl,
0.77g, 4.7 min01,1.5 eq, previously recrystallized from dry THF) in dry THF (15 inI) was
added neat Intermediate 5 (1.00 g, 3.16 minol) over 5 min. The resulting mixture was heated
at 73'C under an inert atmosphere overnight. The reaction mixture was cooled, added to
water (50 in I), and extracted with ethyl acetate (4 x 25 in I). Pooled organic layers were
washed with water (2 x 25 in I) and brine (25 in I), and dried with sodium sulfate. After filtration
and evaporation of solvent, a syrup (0.7 g) was obtained which was purified on silica using
methanol-dichloromethane (20:80). This purification gave 0,245 g of the title compound
(TLC: methanol-chloroform (20:80), Rf=0.55, co-migrating with reference standard; Ms(+)
in/z 3441345), and another 0,070 g of mixture containing the title compound.
The reaction was repeated with another 1.7 g of Intermediate 5 (5.4 minol) with the
modification of using only 1.2 eq CD1 (6.5 minol). This second preparation was purified on
silica using a gradient of methanol-dichloromethane (7:93 to 20:80) to give 0.376 g of tan
solid title compound. As before, a mixture (0,301 g) containing desired product resulted. In
W0 21/12/163773
each purification step, fractions containing more highly pure desired title compound were
determined using HPLC (Eclipse XDB-C18,4.6 x 150 min, 3.5 pin, A=wateracetonitrile-
trifluoroacetic acid (90:10:0. , ), B=wateracetonitrile-trifluoroacetic acid 00:90:0.1), 0%B-
I009'. B over 20 min, rt=9.2 min). Purity of combined product at this stage of the purification
was approximately 90%. Final purification of title compound was accomplished on a column
of Amberchrom CGI61m (4 x 30 cm) using a stepwise gradient elution of wateracetonitrile
(85:15,75:25,67:33). Fractions containing pure product were again determined using RP-
HPLC. Pooled fractions were Iyophilized overnight. Solid product was then redissolved in
methanol-dichloromethane (5:95), and washed with half-saturated sodium bicarbonate and
brine, backwashing all aqueous washes thoroughly. The organic layer was dried with sodium
sulfate, filtered, and solvent evaporated using a heptane azeotrope to yield 0,317 g of the
title compound (0.93 minol).
Technical Data:
Purity by HPLC
Method:
Waters Acquity with ELS detector
Phenomenex Polar RP 4.6 x 150 x 4 pin
A H20
B: MeOH
^, A %B
Time (min)
o 95 5
5 95
9 5 95
Flow: 0.6 in 11min
Result: > 99%
RT: 6.43 min
Isotope Incorporation by Mass Spectrometry
Method
Agilent MSD 1100
Conditions: ES-API ionization mode
Positive Polarity
6 inM Ammonium Formate in Methanol:Water 7:3
Result:
Molecular ion peak of 343 is consistent with expected labelling and mass
spectroscopy ionization method.
W0 21/12/163773 PCT/EP21i12/(159649
Comments:
The compound of (1)* has a total isotopic incorporation of > 99% M+6.
^!^^:
Pre aration of I- IH-Benz d jinidaz01 I 4-h drox
hen I- roc6 -jinidazolidin
one Coin ound of Formula I Coin ound of Formula I '
I"'=^'HN
HO tic,
'0, ,,,, " , ' HO, ,,,;. c, ,,
', 3 <::"' ', 3 I"
BBr3, CH2CH2
13c , 13c N
' 13
c*,,, ' >,,=o
\j. :>,, o
(1),
To a solution of Example 3 (0.200 g, 0.58 minol) in dry dichloromethane at -20'C under an
inert atmosphere was added boron tribromide (0.17 in I, 0.44 g, 1.8 mmol) dropwise. An ice
water cooling bath (0"C) was then used and the reaction was stirred cold for I h. Using a
room temperature water bath, the reaction was stirred for another I h. The reaction was
quenched by slow addition of water (18 inI). An organic layer was reserved, and was re-
extracted with more water. All clear, colorless water layers (pH ~ 3) were combined, cooled
to 5'C, and made basic by addition of I N sodium hydroxide. The aqueous phase was iced
for I h, and centrifuged to give a white precipitate, which was washed with cold water, dried
overnight over Drierite to give 0,138 g requiring additional purification. A column of
Amberchrom CGI 61 in (2 x 30 cm) using a gradient of wateracetonitrile (10:90 to 50:50).
Fractions were analysed by RP-HPLC, and pooled to give two lots of the title compound
(0.038 g and 0,063 g).
Technical Data:
Purity by HPLC
Method:
Zorbax Bonus RP 4.6 x 150 x 5 pin
A H20
B: MeOH
%A %B
Time (min)
PCT/EP21!12/1/59649
W0 21/12/163773
90 10
90 10
5 95
5 95
Flow: I .O in 11min; UV: 254 rim
Result: 97.4 %
RT: 9.88 min and 9.5 min for 210ts
Isotope Incorporation by Mass Spectrometry
Method:
Agilent MSD 1100
Conditions: ES-API ionization mode
Positive Polarity
6 inM Ammonium Formate in Methanol:Water 7:3
Result:
Molecular ion peak of 301 is consistent with expected labelling and mass
spectroscopy ionization method.
Comments:
The compound of (1)' has a total isotopic incorporation of > 99% M+6.
Pre aration of Benzimidazole''C Coin ounds of Formulae '1 ' and 11 '
Coin ounds of Formulae 11 ' and 11 d
intermediate I
11, N
N \N
,./ \
Methanol
-Aminoj2-"Cjbe"zimidazole
Intermediate I
To a suspension of 5-amino[2. 'C]benzimidazole. 2HCl (Supplier 101; Catalogue No. CC-544)
(52.2 inci, 60 inci/mm01,0.87 mmol) in methanol (2 inI) was added potassium carbonate
W0 2/1/21163773 PCT/EP21112/1159649
(468 ing, 3,388 minol) and methylamine (236 PI, 1,694 minol). The mixture was stirred at O'C
for I hour, filtered and rotary evaporated to a brown solid. This brown solid was dissolved in
methanol (I inI) and stirred at O'C. To this was added 2,3-difluorobenzaldehyde (119 ing,
0,837 minol). The solution was allowed to warm to room temperature and stirred for 2 hours'
The solvent was removed by rotary evaporation yielding an oil (52 inci, 60 inci/min01,0,867
mmol).
intermediate 2
CO2Ej
I, 2-Dimethoxyethane
N \N
MIN ,
M, I I o
Intermediate 2
Intermediate I (52 inci, 60 inci/mm01,0867 mmol) was dissolved in 1.2-dimethoxyethane (5
in I). To this was added diethyl oxalpropionate (183 PI, 0,969 minol) and the solution was
refluxed at 95'C for 72 hours,
The product was purified by HPLC on a Gemini C18 column eluting with a 20mM ammonium
hydroxide : methanol gradient system then rotary evaporated to a solid (21.2 inci, 60
inci/mm01,0,353 minol).
intermediate 3
^.>. on
W0 21/12/163773
Intermediate 3
Intermediate 2 (21.2mCi, 60 inci/mm01, 0,353 mmol) was dissolved in concentrated
hydrochloric acid (6 inI) and refluxed at 110'C for 16 hours'
The solid was filtered, suspended in water (10 in I) and basified with saturated sodium
bicarbonate to pH 8.1. Stirring was continued for 30 minutes then the mixture was filtered
and rotary evaporated to a solid (16.2 inci, 60 inci/mm01,0.27 minol).
RacemiclBenzimidazole. 2-''CjCompound of Formula (14)" (Compound of Formula (11)?
TMS-CH2N2
DIPEA
^^>.
Methanol N
(11).
To a stirred solution of Intermediate 3 (16.2 inci, 60 inci/min01,0.27 minol) in methanol (4
in I) was added diisopropylethylamine (53 111,0,303 mmol) followed by
(trimethylsilyl)diazomethane (2M in ether, 275 PI, 0.55 mmol). After 15 minutes a further
aliquot of (trimethylsilyl)diazomethane (275 PI, 0.55 mmol) was added and stirring was
continued for I hour' The solvents were removed by rotary evaporation yielding a solid. The
solid was then purified by HPLC on a Gemini Ci8 column eluting with a 20 inM ammonium
hydroxide: methanol gradient system, then rotary evaporated to a solid.
Pure Isomer 18enzimidazole''Cj Compound of Formula (11)' (Compound of Formula
(14)^)
W0 21/12/163773 PCT/EP21112/(159649
HPLC I
^*---
I, I
(11)'
The racemate compound (11)' was purified by HPLC on a Chirobiotic TAG column eluting with
40 inM ammonium acetate : methanol (4:6). The pure isomer of (11)' was freeze-dried
overnight yielding a white solid (1.94 inci, 60 inci/min01,0,032 in o1).
Technical Data:
Specific Activity
Determined by:
Mass Spectrometry: 60 inci/mmol 2.22 GBq/mmol
357.3
Molecular Weight (at this specific activity):
Radiochemical Purity by HPLC
Column:
Zorbax Bonus RP 3.5 pin (150 x 4.6mm)
Solvent A
Phosphate buffer pH 6.0
Solvent B : Acetonitrile
^. A %B
Gradient:
Time (min)
o 100
100 o
90
100 o
100 o
Temperature: 25'C
I .O in 11min
Flow:
W0 21/12/163773
Detection:
Homogeneous radiochemical detector, DAD at 225 rim
Result: 98,191,
Chiral Purity by HPLC
Column:
Chirobiotic Tag 5 pin (250 x 4.6 mm)
Solvent A:
40 inM ammonium acetate buffer pH 4.0
Solvent B: methanol
Gradient: 60 91. B isocratic for 20 mins
Temperature: 20'C
Flow Rate: I in 11min
Detection:
Homogeneous radiochemical detector, DAD at 220 rim
Result: 98.8%
Biolo ical exam Ies
Small-animal PETp"ot study in rats
Two female Sprague-Dawley rats were treated with compound (1)'.
Rat 7: 109.5 MBq of compound (1)' dissolved in 500 PI 0.9% NaCl/EtOH (911, v/v) were
injected i. v. in the tail vein. The specific activity of labeled compound (1)' was 23.7 GBq/pinol.
The final dose of compound (1)' administered to rat I was 0,009 ing/kg.
Rat 2: 29.5 MBq compound (1)' plus 0.57 ing of the unlabelled form of compound (1)' was
administered i. v. in the tail vein. The final dose of compound (1)' administered to rat 2 was
3.8 ing/kg.
PET Scan
60 min dynamic PET scan of the head regions of rats I and 2 was performed. Blood plasma
samples were taken at the end of the PET scans from retro-orbital regions. The PET
summation images are shown in Figure I.
1.5 in I of the plasma samples were thoroughly mixed with 3.0 in I acetonitrile. After
centrifugation, the supernatant was evaporated at 100'C under an argon atmosphere. The
W0 21/12/163773
PCT/EP21112/(159649
dried residue was dissolved in 2 in I CH, CN/0,191, aq. TFA (9/1 ), spiked with 20 PI unlabeled
compound (1)' (2.3 ing/kg) and radioactivity was determined by HPLC:
Column:
Chromolith Performance RP-18 endcapped 100 - 4,6 min monolithic HPLC-
column (MERCK)
Solvent:
13% Acetonitrile in H20 (0,191. TFA)
Flow rate: 5 in 11min
UV Detection: 225 rim
The time-activity graph is shown in Figure 2. Activity concentrations in the rat brains (total
radio activity) in plasma after the PET Scan were 0,279'. ID/g for rat I and 0.19 %ID/g for rat
Claims (14)
1. A radiolabelled glutaminyl cyclase (QC) inhibitor for use as an imaging agent, wherein said radiolabelled glutaminyl cyclase inhibitor is selected from the group consisting of: a compound of formula (IV): N N O (IV); 10 a compound of formula (V): O CH N N O (V); a compound of formula (I) : * Position C-Label (I) ; a compound of formula (I) : (I) ; a compound of formula (II) : (II) ; and a compound of formula (II) : 10 (II) ; or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof.
2. The use of the radiolabelled glutaminyl cyclase inhibitor of claim 1 in the manufacture 5 of an imaging agent for the detection of a neurological disorder.
3. A pharmaceutical composition comprising a radiolabelled glutaminyl cyclase inhibitor as defined in claim 1 or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, in combination with one or more 10 pharmaceutically acceptable excipients.
4. The pharmaceutical composition of claim 3 for use as an imaging agent in the detection of a neurological disorder. 15
5. The use of claim 2, wherein the neurological disorder is mild cognitive impairment, Alzheimer’s disease, Familial British Dementia, Familial Danish Dementia or neurodegeneration in Down Syndrome and Huntington’s disease.
6. The pharmaceutical composition of claim 4, wherein the neurological disorder is mild 20 cognitive impairment, Alzheimer’s disease, Familial British Dementia, Familial Danish Dementia or neurodegeneration in Down Syndrome and Huntington’s disease.
7. A method for imaging a neurological disorder, said method comprising measuring the affinity of a radiolabelled glutaminyl cyclase inhibitor as defined in claim 1 towards senile 25 plaques.
8. A method for imaging a neurological disorder, said method comprising measuring the affinity of a radiolabelled glutaminyl cyclase inhibitor as defined claim 1 towards tau aggregates.
9. A method for ex vivo or in vitro detection of amyloid deposits in a brain tissue, the method comprising treating the tissue with an inhibitor as defined in claim 1 for detection of the amyloid deposit. 35
10. A method for ex vivo or in vitro detection of tau proteins in a brain tissue, the method comprising treating the tissue with a radiolabelled glutaminyl cyclase inhibitor as defined in claim 1 for detection of the neurofibrillary tangles.
11. The method of claim 7 or 8, wherein the imaging is performed using gamma imaging, magnetic resonance imaging, magnetic resonance spectroscopy or fluorescence spectroscopy. 5
12. The method of claim 9 or 10, wherein the detection is performed using gamma imaging, magnetic resonance imaging, magnetic resonance spectroscopy or fluorescence spectroscopy.
13. The method of claim 11, wherein the gamma imaging is PET or SPECT.
14. The method of claim 12, wherein the detection by gamma imaging is PET or SPECT. W0 21/
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490654P | 2011-05-27 | 2011-05-27 | |
US61/490,654 | 2011-05-27 | ||
PCT/EP2012/059649 WO2012163773A1 (en) | 2011-05-27 | 2012-05-24 | Radiolabelled glutaminyl cyclase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617581A NZ617581A (en) | 2016-03-31 |
NZ617581B2 true NZ617581B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9610368B2 (en) | Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same | |
EP2501696B1 (en) | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases | |
AU2012304359B2 (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
CA2794004C (en) | Imaging agents for detecting neurological disorders | |
BRPI0808503B1 (en) | COMPOUND, USE OF A COMPOUND, AND PHARMACEUTICAL COMPOSITION | |
JP5322180B2 (en) | PET probe having alkoxy groups substituted with fluorine and hydroxy groups | |
TW201026336A (en) | Benzothiazole amides for detection of amyloid beta | |
US9724435B2 (en) | Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders | |
NZ617581B2 (en) | Radiolabelled glutaminyl cyclase inhibitors | |
WO2011141515A1 (en) | Diagnostic agents for amyloid beta imaging | |
US20110217234A1 (en) | Imaging ligands | |
US20110280804A1 (en) | Highly selective sigma receptor radioligands | |
SagsttaS'Transversa | Heiser et al.(43) Pub. Date: Nov. 29, 2012 | |
CA2941634C (en) | Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders | |
JP2021102593A (en) | New compound imaging tau | |
JP2009203166A (en) | Diagnostic composition containing diphenyloxadiazole derivative | |
Class et al. | Patent application title: HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS Inventors: Christopher R. Mccurdy (Oxford, MS, US) Christophe Mesangeau (Hellemmes, FR) Frederick T. Chin (Sunnyvale, CA, US) Michelle L. James (Menlo Park, CA, US) Bin Shen (Mountain View, CA, US) Sanjiv Gambhir (Portola Valley, CA, US) Sandip Biswal (Stanford, CA, US) Deepak Behera (Fremont, CA, US) | |
WO2011124713A1 (en) | Labelled huprine derivatives and their use in medical imaging |